Investor attention is shifting toward a key scientific conference as shares of biotechnology firm Veru Inc. trade quietly. The company is scheduled to deliver multiple presentations on its lead drug ...

Certain men face a far greater risk of prostate cancer – yet many will still not be routinely offered testing under new ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

Objectives: Molecular tumor boards (MTBs) have become an integral component of precision oncology, yet data on their real-world impact in urologic cancers are limited. This study aimed to characterize ...

A new research has revealed a clear association between chronic periodontitis and gynecological disorders such as PCOD and ...

The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...

Recent polling shows oncologists changing inclination in treatment for mHSPC based on tolerability profiles.

The optimal time to measure PSA response to treatment is the one that best predicts metastatic hormone-sensitive prostate cancer (mHSPC) progression.

近期，基于VISION[1] 和PSMAfore研究[2]的积极结果，国家药品监督管理局（NMPA）已批准镥 [177Lu]特昔维匹肽用于治疗前列腺特异性膜抗原（PSMA）阳性的 mCRPC 患者，覆盖了「ARPI + 化疗经治」和「ARPI ...